Detail akcie AB Science online

Business Summary: AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The Company is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.
Financial Summary: BRIEF: For the six months ended 30 June 2023, AB Science SA revenues decreased 29% to EUR448K. Net loss increased 46% to EUR10.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Financial Income - Remaining Value decrease of 74% to EUR884K (income), Other Financial Expenses increase from EUR647K to EUR1.6M (expense).